Abstract:Rationale: Circular RNA (circRNA) therapeutics hold great promise as an iteration strategy in messenger RNA (mRNA) therapeutics due to their inherent stability and durable protein translation capability. Nevertheless, the efficiency of RNA circularization remains a significant constraint, particularly in establishing large-scale manufacturing processes for producing highly purified circRNAs. Hence, it is imperative to develop a universal and more efficient RNA circularization system when considering synthetic circRNAs as therapeutic agents with prospective clinical applications. Methods: We initially developed a chimeric RNA circularization system based on the original permuted intron-exon (PIE) and subsequently established a high-performance liquid chromatography (HPLC) method to obtain highly purified circRNAs. We then evaluated their translational ability and immunogenicity. The circRNAs expressing human papillomavirus (HPV) E7 peptide (43-62aa) and dimerized receptor binding domain (dRBD) from SARS-CoV-2 were encapsulated within lipid nanoparticles (LNPs) as vaccines, followed by an assessment of the in vivo efficacy through determination of antigen-specific T and B cell responses, respectively. Results: We have successfully developed a universal chimeric permuted intron-exon system (CPIE) through engineering of group I self-splicing introns derived from Anabaena pre-tRNALeu or T4 phage thymidylate (Td) synthase gene. Within CPIE, we have effectively enhanced RNA circularization efficiency. By utilizing size exclusion chromatography, circRNAs were effectively separated, which exhibit low immunogenicity and sustained potent protein expression property. In vivo data demonstrate that the constructed circRNA vaccines can elicit robust immune activation (B cell and/or T cell responses) against tumor or SARS-CoV-2 and its variants in mouse models. Conclusions: Overall, we provide an efficient and universal system to synthesize circRNA in vitro, which has extensive application prospect for circRNA therapeutics.

Engineering circular RNA for enhanced protein production

Engineering circular RNA for molecular and metabolic reprogramming

CircPro: an Integrated Tool for the Identification of Circrnas with Protein-Coding Potential.

Engineering circular RNA regulators to specifically promote circular RNA production

A Simple and Efficient One-Step Synthesis System for Flexible Production of Circular RNA in E. coli

Circular RNA: an emerging key player in RNA world.

Efficient circularization of protein-encoding RNAs via a novel cis -splicing system

Synthetic circular RNA switches and circuits that control protein expression in mammalian cells

Robust genome and cell engineering via in vitro and in situ circularized RNAs

Chemical circularization of in vitro transcribed RNA opens new avenues for circular mRNA design

A Highly Efficient Strategy for Overexpressing circRNAs.

Systematic screen of RNA binding proteins that enhance circular RNA translation

Circular mRNA: A novel therapeutic agent

Tactics targeting circular mRNA biosynthesis

Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics

Analytical Methods and Platforms for circRNA Vector Engineering to Improve Circularization Efficiency

Advances in Engineering Circular RNA Vaccines

RNAe: an Effective Method for Targeted Protein Translation Enhancement by Artificial Non-Coding RNA with SINEB2 Repeat

Utility of oligonucleotide in upregulating circular RNA production in a cellular model

Circular RNA translation, a path to hidden proteome

Study of circular RNA translation using reporter systems in living cells